

## DAFTAR PUSTAKA

- ADA. (2020). 1. *Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes — 2020*. *Diabetes Care*, 43(Supplement\_1), S7–S13. <https://doi.org/10.2337/dc20-S001>
- Ågesen, F. N., Weeke, P. E., Tfelt-Hansen, P., & Tfelt-Hansen, J. (2019). *Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology*. *Pharmacology Research & Perspectives*, 7(4). <https://doi.org/10.1002/prp2.496>
- Alfaraidi, H., & Samaan, M. C. (2023). *Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review*. *Frontiers in Endocrinology*, 13. <https://doi.org/10.3389/fendo.2022.1072879>
- Alshahrani, S. (2023). *Renin–angiotensin–aldosterone pathway modulators in chronic kidney disease: A comparative review*. *Frontiers in Pharmacology*, 14. <https://doi.org/10.3389/fphar.2023.1101068>
- Amin, N. U., Sabir, F., Amin, T. B., Sarfraz, Z., Sarfraz, A., Robles-Velasco, K., & Chérrez-Ojeda, I. (2022). *SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials*. *Healthcare*, 10(12), 2356. <https://doi.org/10.3390/healthcare10122356>
- A'udina. (2020). *Sejarah Artikel: Diterima 19 Januari*. <https://doi.org/10.15294/higeia.v4iSpecial%203/40392>
- Ayutthaya, S. S., & Adnan, N. (2020). *Faktor Risiko Hipertensi pada Penderita Diabetes Mellitus Tipe 2*. *Jurnal Ilmu Kesehatan Masyarakat*, 9(02). <https://doi.org/10.33221/jikm.v9i02.512>
- Benes, J., Kotrc, M., Kroupova, K., Wohlfahrt, P., Kovar, J., Franekova, J., Hegarova, M., Hoskova, L., Hoskova, E., Pelikanova, T., Jarolim, P., Kautzner, J., & Melenovsky, V. (2022). *Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HF<sub>r</sub>EF)*. *Scientific Reports*, 12(1), 13038. <https://doi.org/10.1038/s41598-022-17327-4>
- Chan, J. C. N., Yang, A., Chu, N., & Chow, E. (2024). *Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin*.

- Diabetes, Obesity and Metabolism*, 26(S3), 55–74.  
<https://doi.org/10.1111/dom.15700>
- Chulkov, V. S., Gasanov, M. Z., Azovtseva, O. V., Minina, E. E., & Chulkov, V. S. (2024). *The role of beta blockers in the treatment of cardiovascular diseases. Meditsinskiy sovet = Medical Council*, 16, 28–36.  
<https://doi.org/10.21518/ms2024-467>
- Das, U., Paul, A., & Banerjee, S. (2021). *SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction. The Egyptian Heart Journal*, 73(1).  
<https://doi.org/10.1186/s43044-021-00218-w>
- Dludla, P. V., Mabhida, S. E., Ziqubu, K., Nkambule, B. B., Mazibuko-Mbeje, S. E., Hanser, S., Basson, A. K., & Kengne, A. P. (2023). *Pancreatic B-Cell Dysfunction in Type 2 Diabetes: Implications of Inflammation and Oxidative Stress. World Journal of Diabetes*. <https://doi.org/10.4239/wjd.v14.i3.130>
- Du, Y., Zhu, Y.-J., Zhou, Y.-X., Ding, J., & Liu, J.-Y. (2022). *Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study. Molecular Biomedicine*, 3(1), 41.  
<https://doi.org/10.1186/s43556-022-00108-w>
- Dutta, S., Shah, R. B., Singhal, S., Dutta, S. B., Bansal, S., Sinha, S., & Haque, M. (2023). *Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes. Drug Design, Development and Therapy, Volume 17*, 1907–1932. <https://doi.org/10.2147/DDDT.S409373>
- Elrakaybi, A., Laubner, K., Zhou, Q., Hug, M. J., & Seufert, J. (2022). *Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role? Molecular Metabolism*, 64, 101549.  
<https://doi.org/10.1016/j.molmet.2022.101549>
- Fonseca, V., Bakris, G. L., Bell, D. S. H., McGill, J. B., Raskin, P., Messerli, F. H., Phillips, R. A., Katholi, R. E., Wright, J. T., Waterhouse, B., Lukas, M. A., & Anderson, K. M. (2007). *Differential effect of  $\beta$ -blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabetic Medicine*, 24(7), 759–763. <https://doi.org/10.1111/j.1464-5491.2007.02151.x>

- Grossman, A., & Grossman, E. (2017). *Blood pressure control in type 2 diabetic patients. Cardiovascular Diabetology*, 16(1), 3. <https://doi.org/10.1186/s12933-016-0485-3>
- Indriastuti, M., & Harun, N. (2020). *Comparative Pharmacoeconomy and Effectiveness of Combination Antiplatelet Cost in Patient Ischemic Stroke. Journal of Physics: Conference Series*, 1477(6). <https://doi.org/10.1088/1742-6596/1477/6/062004>
- Kim, K. (2024). *Rethinking about Metformin: Promising Potentials. Korean Journal of Family Medicine*, 45(5), 258–267. <https://doi.org/10.4082/kjfm.24.0156>
- Kinanti, W., Andayani, T. M., & Irijanto, F. (2022). Perbandingan Efektivitas Angiotensin Receptor Blocker (ARB) dengan Calcium Channel Blocker (CCB) Pada Pasien Penyakit Ginjal Kronis dengan Hemodialisis. *JPSCR: Journal of Pharmaceutical Science and Clinical Research*, 7(1), 28. <https://doi.org/10.20961/jpscr.v7i1.53514>
- Numlil, & Ilfasa. (2025). Studi Penggunaan  $\beta$ -Blocker pada Pasien Gagal Jantung di Instalasi Rawat Inap RSJPD Harapan Kita Tahun 2022. <https://doi.org/10.15416/ijcp.2025.v14i01.53666>
- Pinon, A., Allignol, A., Hohenberger, T., Foch, C., Boutmy, E., & Hostalek, U. (2024). *Dependent censoring bias assessment using inverse probability of censoring weights: Type 2 diabetes mellitus risk in patients initiating bisoprolol versus other antihypertensives in a Clinical Practice Research Datalink cohort study. Journal of Comparative Effectiveness Research*, 13(11). <https://doi.org/10.57264/cer-2023-0027>
- Robbani, N. N. F., Purwaningsih, S., Rahmianti, N. D., & Ardiana, M. (2024). *The Role of Candesartan in Heart Failure Management: A Literature Review. International Journal Of Scientific Advances*, 5(6). <https://doi.org/10.51542/ijscia.v5i6.62>
- Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023). *Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management*

- of *Diabetes Mellitus*. *Diabetes care*, 46(10), e151–e199.  
<https://doi.org/10.2337/dci23-0036>
- Seferović, P. M., Petrie, M. C., Filippatos, G. S., Anker, S. D., Rosano, G., Bauersachs, J., Paulus, W. J., Komajda, M., Cosentino, F., de Boer, R. A., Farmakis, D., Doehner, W., Lambrinou, E., Lopatin, Y., Piepoli, M. F., Theodorakis, M. J., Wiggers, H., Lekakis, J., Mebazaa, A., ... McMurray, J. J. V. (2018). *Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology*. *European Journal of Heart Failure*, 20(5), 853–872.  
<https://doi.org/10.1002/ejhf.1170>
- Setia Permana, D. A. (2023). Kajian Interaksi Obat Diabetes Mellitus Tipe II Dengan Penyakit Penyerta Hipertensi Di UPTD Puskesmas Cilacap “X.” *Jurnal Kesehatan Qamarul Huda*, 11(1), 335–342.  
<https://doi.org/10.37824/jkqh.v11i1.2023.483>
- Sheleme, T. (2021). *Clinical Pharmacokinetics of Metformin*. Dalam *Metformin - Pharmacology and Drug Interactions*. IntechOpen.  
<https://doi.org/10.5772/intechopen.99343>
- Shrestha, N., Franco, E. De, Arvan, P., & Cnop, M. (2021). *Pathological B-Cell Endoplasmic Reticulum Stress in Type 2 Diabetes: Current Evidence*. *Frontiers in Endocrinology*. <https://doi.org/10.3389/fendo.2021.650158>
- Suksomboon, N., Poolsup, N., & Prasit, T. (2012). *Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes*. *Journal of Clinical Pharmacy and Therapeutics*, 37(3), 319–327. <https://doi.org/10.1111/j.1365-2710.2011.01295.x>
- Sylvestris, A. (2017). HIPERTENSI DAN RETINOPATI HIPERTENSI. *Saintika Medika*, 10(1). <https://doi.org/10.22219/sm.v10i1.4142>
- Telaumbanua, A. C., & Rahayu, Y. (2021). PENYULUHAN DAN EDUKASI TENTANG PENYAKIT HIPERTENSI. *Jurnal Abdimas Saintika*, 3(1).  
<https://doi.org/10.30633/jas.v3i1.1069>

- Tran Nguyen, P. D. (2024). *Hypoglycemic and Glucose Lowering Properties of <i>Cordyceps Militaris</i>*, *Tropical Journal of Pharmaceutical Research*. <https://doi.org/10.4314/tjpr.v22i12.20>
- Unja, E. E., Britama, B., & Trihandini, B. (2024). *The Relationship Between Blood Glucose Levels and Hypertension in Type 2 Diabetes Mellitus Patients in the Working Area of Teluk Tiram Public Health Center, Banjarmasin City, 2024*. *Journal of Nursing Invention*, 5(2), 130–138. <https://doi.org/10.33859/jni.v5i2.677>
- Wu, V. C., Li, Y., & Wang, C.-Y. (2021). *Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection*. *International Journal of Molecular Sciences*. <https://doi.org/10.3390/ijms22137170>